Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;40(6):209-213.
doi: 10.18773/austprescr.2017.066. Epub 2017 Dec 4.

Functional dyspepsia

Nicholas J Talley  1 , Thomas Goodsall  2 , Michael Potter  2
Affiliations
Review

Functional dyspepsia

Nicholas J Talley et al. Aust Prescr. 2017 Dec.
No abstract available

Keywords: H2 receptor antagonists; dyspepsia; endoscopy; gastro-oesophageal reflux; proton pump inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Nicholas Talley has received grants and research support from: Abbott Pharmaceuticals (IBS), Commonwealth Diagnostics (International), Janssen (constipation), Prometheus (IBS), Pfizer (at Mayo Clinic), Rome Foundation and Salix (at Mayo Clinic). He has patents on: biomarkers of irritable bowel syndrome, licensing questionnaires (Mayo Clinic), Nestec European Patent Application No. 12735358.9 and New Singapore ‘Provisional’ Patent NTU Ref: TD/129/17 ‘Microbiota Modulation of BDNF Tissue Repair Pathway’. He has been involved with the following consultancies: Adelphi Values (functional dyspepsia working group to develop a symptom-based PRO instrument), Allergens PLC (GI development programs), GI therapies (non-invasive device company, consultant and options), Napo Pharmaceutical, Outpost Medicine, Samsung Bioepis and Yuhan (IBS).

References

    1. Aro P, Talley NJ, Agréus L, Johansson SE, Bolling-Sternevald E, Storskrubb T, et al. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther 2011;33:1215-24. Available from: https://doi.org/10.1111/j.1365-2036.2011.04640.x 10.1111/j.1365-2036.2011.04640.x - DOI - DOI - PubMed
    1. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther 2013;38:170-7. Available from: https://doi.org/10.1111/apt.12355 10.1111/apt.12355 - DOI - DOI - PubMed
    1. Koloski NA, Jones M, Talley NJ. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study. Aliment Pharmacol Ther 2016;44:592-600. Available from: https://doi.org/10.1111/apt.13738 10.1111/apt.13738 - DOI - DOI - PubMed
    1. Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med 2015;373:1853-63. Available from: https://doi.org/10.1056/NEJMra1501505 10.1056/NEJMra1501505 - DOI - DOI - PubMed
    1. Koloski NA, Jones M, Weltman M, Kalantar J, Bone C, Gowryshankar A, et al. Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia. Neurogastroenterol Motil 2015;27:1317-25. Available from: https://doi.org/10.1111/nmo.12626 10.1111/nmo.12626 - DOI - DOI - PubMed

FURTHER READING

    1. Keung C, Hebbard G. The management of gastro-oesophageal reflux disease. Aust Prescr 2016;39:6-10. Available from: https://doi.org/10.18773/austprescr.2016.003 10.18773/austprescr.2016.003 - DOI - DOI - PMC - PubMed

LinkOut - more resources